Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010_505 | Other Identifier | Merck Registration Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and will evaluate the safety and tolerability of suvorexant both in participants with impaired renal function and in healthy participants.
Study Design:
This study plans to enroll 16 participants in Part I (8 participants with severe renal impairment and a control group of 8 healthy participants) and 32 participants in Part II (8 participants with moderate renal impairment and a control group of 8 healthy participants; and 8 participants with mild renal impairment and a control group of 8 healthy participants).
Part II will be conducted only if the primary hypothesis is not met in Part I and there is a significant difference in the PK of suvorexant between healthy participants and severe renal impairment participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with Severe Renal Impairment (Part I) | Experimental | Participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study. |
|
| Healthy Participants (Severe Impairment Controls) (Part I) | Experimental | Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study. |
|
| Participants with Moderate Renal Impairment (Part II) | Experimental | Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study. |
|
| Healthy Participants (Moderate Impairment Controls) (Part II) | Experimental | Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study. |
|
| Participants with Mild Renal Impairment (Part II) | Experimental | Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Suvorexant | Drug | single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus Healthy Participants (Part I) | Overall exposure was assessed by the area under the plasma concentration versus time curve from time zero to infinity (AUC[0-∞]). AUC(0-∞) was calculated as the sum of the AUC to the last time point with a detectable plasma concentration (AUC[0-last]) and the extrapolated area given by the quotient of the last detectable concentration and the apparent terminal rate constant (λ). | Predose and 0.5, 1, 2, 4, 6, 9, 12, 16, 24, 48, 72, 96, and 120 hours post-dose |
| AUC(0-∞) After Single Dose Suvorexant: Moderate and Mild Renal Impairment Participants Versus Healthy Participants (Part II) | Overall exposure was assessed by the area under the plasma concentration versus time curve from time zero to infinity (AUC[0-∞]). AUC(0-∞) was calculated as the sum of the AUC to the last time point with a detectable plasma concentration (AUC[0-last]) and the extrapolated area given by the quotient of the last detectable concentration and the apparent terminal rate constant (λ). | Predose and 0.5, 1, 2, 4, 6, 9, 12, 16, 24, 48, 72, 96, and 120 hours post-dose |
| Number of Participants With an Adverse Event (AE) | An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. | From administration of study drug through 14 days after administration of study drug |
| Number of Participants Who Discontinued Study Due to an AE | An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. | From administration of study drug through 14 days after administration of study drug |
Not provided
Not provided
Inclusion Criteria:
Impaired Renal Function Participants:
Healthy Participants:
Exclusion Criteria:
Impaired Renal Function Participants:
Healthy Participants:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
Not provided
| ID | Type | URL | Comment |
|---|---|---|---|
| CSR Synopsis | View IPD |
Not provided
Not provided
Not provided
16 participants were enrolled in Part I of the study. Because the primary hypothesis was met in Part I, no participants were enrolled in Part II of the study.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Participants With Severe Renal Impairment (Part I) | Participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. |
| FG001 | Healthy Participants (Severe Impairment Controls) (Part I) | Healthy participants matched to participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. |
| FG002 | Participants With Moderate Renal Impairment (Part II) | Participants with moderate renal impairment were to receive a single dose of 20 mg open-label suvorexant during Part II of the study. No participants were enrolled in this arm. |
| FG003 | Healthy Participants (Moderate Impairment Controls) (Part II) | Healthy participants matched to participants with moderate renal impairment were to receive a single dose of 20 mg open-label suvorexant during Part II of the study. No participants were enrolled in this arm. |
| FG004 | Participants With Mild Renal Impairment (Part II) | Participants with mild renal impairment were to receive a single dose of 20 mg open-label suvorexant during Part II of the study. No participants were enrolled in this arm. |
| FG005 | Healthy Participants (Mild Impairment Controls) (Part II) | Healthy participants matched to participants with mild renal impairment were to receive a single dose of 20 mg open-label suvorexant during Part II of the study. No participants were enrolled in this arm. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Baseline characteristics were only presented for participants in Part I of the study (N=16). No participants were enrolled in Part II of the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Participants With Severe Renal Impairment (Part I) | Participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. |
| BG001 | Healthy Participants (Part I) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus Healthy Participants (Part I) | Overall exposure was assessed by the area under the plasma concentration versus time curve from time zero to infinity (AUC[0-∞]). AUC(0-∞) was calculated as the sum of the AUC to the last time point with a detectable plasma concentration (AUC[0-last]) and the extrapolated area given by the quotient of the last detectable concentration and the apparent terminal rate constant (λ). | All Treated Participants | Posted | Geometric Mean | 95% Confidence Interval | μM•hr | Predose and 0.5, 1, 2, 4, 6, 9, 12, 16, 24, 48, 72, 96, and 120 hours post-dose |
|
From administration of study drug through 14 days after administration of study drug
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants With Severe Renal Impairment (Part I) | Participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| dry mouth | Gastrointestinal disorders | MedDRA 13.1 |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C551624 | suvorexant |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Healthy Participants (Mild Impairment Controls) (Part II) | Experimental | Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study. |
|
|
Healthy participants matched to participants with severe renal impairment received a single dose of 20 mg open-label suvorexant.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Healthy Participants (Part I) | Healthy participants matched to participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. |
|
|
|
| Primary | AUC(0-∞) After Single Dose Suvorexant: Moderate and Mild Renal Impairment Participants Versus Healthy Participants (Part II) | Overall exposure was assessed by the area under the plasma concentration versus time curve from time zero to infinity (AUC[0-∞]). AUC(0-∞) was calculated as the sum of the AUC to the last time point with a detectable plasma concentration (AUC[0-last]) and the extrapolated area given by the quotient of the last detectable concentration and the apparent terminal rate constant (λ). | Per protocol, the decision to conduct Part II of study in moderate/mild renal impairment participants was conditional on results of AUC (0-∞) analysis in severe renal impairment participants (Part I). Based on results of Part I of study, Part II was not conducted and AUC(0-∞) analysis in moderate/mild renal impairment was not done. | Posted | Predose and 0.5, 1, 2, 4, 6, 9, 12, 16, 24, 48, 72, 96, and 120 hours post-dose |
|
|
| Primary | Number of Participants With an Adverse Event (AE) | An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. | All Treated Participants | Posted | Number | participants | From administration of study drug through 14 days after administration of study drug |
|
|
|
| Primary | Number of Participants Who Discontinued Study Due to an AE | An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. | All Treated Participants | Posted | Number | participants | From administration of study drug through 14 days after administration of study drug |
|
|
|
| 0 |
| 8 |
| 2 |
| 8 |
| EG001 | Healthy Participants (Part I) | Healthy participants matched to participants with severe renal impairment received a single dose of 20 mg open-label suvorexant. | 0 | 8 | 4 | 8 |
| headache | Nervous system disorders | MedDRA 13.1 |
|
| somnolence | Nervous system disorders | MedDRA 13.1 |
|
| oligomenorrhoea | Reproductive system and breast disorders | MedDRA 13.1 |
|
The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.
| D001523 |
| Mental Disorders |